DGS Capital Management LLC Buys 13,948 Shares of InMode Ltd. (NASDAQ:INMD)

DGS Capital Management LLC lifted its stake in shares of InMode Ltd. (NASDAQ:INMD) by 129.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,704 shares of the healthcare company’s stock after purchasing an additional 13,948 shares during the period. DGS Capital Management LLC’s holdings in InMode were worth $413,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in INMD. Systematic Financial Management LP increased its holdings in InMode by 13.3% during the third quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company’s stock worth $16,647,000 after buying an additional 115,492 shares during the last quarter. Barclays PLC increased its stake in shares of InMode by 113.5% during the 3rd quarter. Barclays PLC now owns 169,630 shares of the healthcare company’s stock worth $2,876,000 after purchasing an additional 90,173 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of InMode by 54.1% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,480 shares of the healthcare company’s stock valued at $2,127,000 after purchasing an additional 44,058 shares during the period. Hsbc Holdings PLC lifted its stake in InMode by 129.7% in the 2nd quarter. Hsbc Holdings PLC now owns 90,280 shares of the healthcare company’s stock valued at $1,659,000 after purchasing an additional 50,974 shares during the last quarter. Finally, State Street Corp grew its holdings in InMode by 3.7% during the third quarter. State Street Corp now owns 2,044,640 shares of the healthcare company’s stock worth $34,657,000 after purchasing an additional 73,183 shares during the period. Institutional investors own 68.04% of the company’s stock.

InMode Trading Down 0.1 %

InMode stock opened at $17.25 on Friday. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of 9.32 and a beta of 2.12. InMode Ltd. has a 12 month low of $14.87 and a 12 month high of $26.80. The stock’s 50 day moving average is $17.64 and its 200-day moving average is $17.24.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on INMD shares. Needham & Company LLC restated a “hold” rating on shares of InMode in a research note on Thursday, October 31st. BTIG Research initiated coverage on InMode in a research note on Thursday, October 17th. They issued a “buy” rating and a $25.00 price target on the stock. Finally, Barclays cut their price target on InMode from $27.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 9th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $22.40.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.